Board of Directors
The board of directors of Global Blood Therapeutics is made up of individuals with broad experience and success in the biopharmaceutical industry, as well as the broader political and business community. Our board plays a critical role in providing guidance to the direction of the company.
Mr. Brown has served as a member of GBT’s board of directors since January 2015. He has more than 50 years of political, business and non-profit experience. He currently serves as an attorney at law representing clients before state and local governments. Prior to that, Mr. Brown served as the 41st mayor of San Francisco. He served more than 30 years in the California State Assembly, spending more than 14 years as Speaker. He currently serves as chairman and chief executive officer of The Willie L. Brown, Jr., Institute on Politics and Public Service, an independent, non-profit organization providing a forum for non-partisan education, debate and discussion of public policy issues. Mr. Brown holds a degree in political science from San Francisco State University and a J.D. from the University of California, Hastings College of the Law. He has received over 17 honorary degrees from prestigious institutions.
Dr. Love joined GBT in June 2014 as president and chief executive officer with broad leadership and management experience in the biotech/pharmaceutical industry. Before that, he was executive vice president, research and development and technical operations at Onyx Pharmaceuticals, Inc., where he played an instrumental role in initiating and completing several of Onyx’s first Phase 3 clinical trials. Prior to Onyx, Dr. Love served as president, chief executive officer and chairman of Nuvelo, Inc., where he led growth of the company to a market capitalization of $1 billion. Prior to that, he served as senior vice president, development at Theravance, Inc. Earlier in his career, Dr. Love held a number of senior management positions in medical affairs and product development at Genentech, where he served as chairman of Genentech’s Product Development Committee. As vice president, product development, Dr. Love oversaw the development strategy and execution leading to approvals of Rituxan®, Herceptin®, Xolair®, TNKase®, Raptiva and Avastin®. Dr. Love has served as a consultant in medicine in the Department of Cardiology at the Massachusetts General Hospital. He currently serves on the board of directors of Amicus Therapeutics, Inc., Portola Pharmaceuticals, Inc. and the Biotechnology Innovation Organization. Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital.
Mr. Morrison has served as a member of GBT’s board of directors since January 2016. He had a 35-year career in public accounting, serving public and private companies in the life sciences sector. Mr. Morrison was a partner at Ernst & Young LLP and served as its U.S. Life Sciences Leader. He has worked on hundreds of public and private financings, including more than 40 IPOs and 100 follow-on offerings. He is considered an expert in the M&A arena. Mr. Morrison currently serves on the board of directors of Audentes Therapeutics, Corvus Pharmaceuticals and Symic Bio. He has served on numerous life sciences industry boards, including the Biotechnology Innovation Organization (BIO) ECS Board, the Bay Area Bioscience Center, the California Life Sciences Foundation, and the Biotechnology Institute. Mr. Morrison holds a B.S. in accounting and finance from the University of California, Berkeley. He is a certified public accountant (inactive).
Mr. Perry has served as a member of GBT’s board of directors since April 2015. He has extensive experience serving in professional and management positions in the biotechnology industry. Previously, he served as an entrepreneur-in-resident at Third Rock Ventures, a venture capital firm. Currently, he serves on various boards of companies and non-profit organizations. Previously, he was president and chief executive officer of Aerovance, a biotechnology company. Prior to that, he was the senior business advisor for Gilead Sciences, Inc., and was an executive officer during which time he served in a variety of capacities, including general counsel, chief financial officer and executive vice president of operations. Earlier in his career, he served as an attorney and partner at Cooley LLP. Mr. Perry currently serves on the board of directors of Nvidia Corporation and MyoKardia, Inc. He received a B.A. in history from the University of California, Berkeley, and a J.D. from the University of California, Davis.
Dr. Pierce has served as a member of GBT’s board of directors since February 2016. He has decades of experience leading research and development at biotechnology and biopharmaceutical firms. Currently, he is an independent consultant and entrepreneur-in-residence at Third Rock Ventures, a venture capital firm. He also serves on the World Federation of Hemophilia (WFH) and WFH USA Board of Directors and the National Hemophilia Foundation (NHF) (U.S.) Medical and Scientific Advisory Council. Dr. Pierce is also a director of Voyager Therapeutics. Previously, he was senior vice president of Hematology, Cell and Gene Therapies at Biogen, where he had overall R&D responsibility for hemophilia and hemoglobinopathies. As chief medical officer at Biogen, he led the research and clinical development of extended half-life FVIII and FIX Fc fusions, which culminated in multiple regulatory approvals. Dr. Pierce was also responsible for global medical affairs for Biogen’s portfolio, and he spearheaded the initiation of a five-year Humanitarian Aid clotting factor distribution program with WFH, and My Life Our Future, a population-wide genomic biobank initiative with NHF and other partners. He is the co-author of more than 150 scientific papers and is a named inventor in over 15 patents. He served on the Blood Products Advisory Committee at the U.S. Food and Drug Administration and the Committee on Blood Safety and Availability at the U.S. Department of Health and Human Services. Dr. Pierce received an M.D. and a Ph.D. in immunology from Case Western Reserve University and did postgraduate training in pathology and hematology research at Washington University.
Dr. Pizzo has served as a member of GBT’s board of directors since September 2015. He is a leader in academic medicine, championing programs and policies to improve the future of science, education and healthcare in the United States and beyond. He currently serves as the David and Susan Heckerman Professor of Pediatrics and of Microbiology and Immunology at Stanford School of Medicine and is a founding director of the Stanford Distinguished Careers Institute. He also serves on the board of directors of MRI Interventions, Inc., a medical device company. He previously served as dean of the Stanford School of Medicine, where he was also the Carl and Elizabeth Naumann Professor of Pediatrics and of Microbiology and Immunology. Before joining Stanford, he was the physician-in-chief of Children’s Hospital in Boston and chair of the Department of Pediatrics at Harvard Medical School. Prior to that, Dr. Pizzo was at the National Cancer Institute, eventually serving as chief of pediatrics and acting scientific director in the Division of Clinical Sciences. Dr. Pizzo is the author of more than 630 scientific articles and 16 books and monographs. He serves on several international boards. Dr. Pizzo received a B.A. from Fordham University and an M.D. from the University of Rochester School of Medicine.
Ms. Svoronos has served as a member of GBT’s board of directors since December 2018. She has more than 30 years of experience in the biopharmaceutical industry in the United States, Canada, Europe and Asia. Most recently, she served as interim chief commercial officer for Medivation, Inc. Before that, she spent nearly 25 years at Merck & Co., Inc., where she held positions of increasing seniority and leadership, including president of Europe/Canada; vice president of Asia Pacific; and vice president, global marketing, for the Arthritis, Analgesics and Osteoporosis franchise. Earlier in her career, she held positions at Webber Pharmaceuticals and Allergan. Ms. Svoronos sits on the boards of several public companies including Endocyte and PTC Therapeutics. She received a B.A. in English and French literature from Carleton University in Ottawa, Canada.
Ms. Yarno has served as a member of GBT’s board of directors since December 2017. She has more than 25 years of experience in the biopharmaceutical industry, including at Merck & Co., Inc., where she held positions of increasing seniority, most recently as chief marketing officer. In that position, she led a global organization charged with all aspects of supporting pre-and post-launch commercialization of pharmaceuticals in more than 20 therapeutic areas. She also served as general manager, Cardiovascular/Metabolic U.S. Business Unit and as Merck’s senior vice president of human resources. Earlier in her career, she was vice president of the Women’s Health Care Franchise for Johnson & Johnson’s Ortho McNeil Pharmaceutical subsidiary. Ms. Yarno has served as a member of the board of several public and private biotechnology and medical device companies, including St. Jude Medical, Medivation, ADial Pharmaceuticals, Durata Therapeutics and Plurogen Therapeutics. Currently, she is a member of the boards of Alder Biopharmaceuticals, Inovio Pharmaceuticals and MyoKardia. Ms. Yarno received an M.B.A. from Temple University, Fox School of Business, and a B.S. in business administration from Portland State University.